Transcriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia

被引:3
作者
Patterson, Shaun D. [1 ]
Huang, Xu [1 ]
Jorgensen, Heather G. [1 ]
Michie, Alison M. [1 ]
机构
[1] Univ Glasgow, Inst Canc Sci, Coll MVLS, Paul OGorman Leukaemia Res Ctr, Glasgow G120ZD, Scotland
来源
HEMATO | 2021年 / 2卷 / 03期
关键词
leukaemia; NFAT; myeloid; cell cycle; differentiation; AML; ACTIVATED-T-CELLS; NUCLEAR-FACTOR; GENE-EXPRESSION; CD34(+) CELLS; C/EBP-ALPHA; KAPPA-B; IDENTIFICATION; CALCINEURIN; PROTEINS; FLT3;
D O I
10.3390/hemato2030035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute myeloid leukaemia (AML) is a haematological cancer with poor outcomes due to a lack of efficacious targeted therapies. The Nuclear Factor of Activated T Cells (NFAT) family of transcription factors is well characterised as a regulator of the cell cycle and differentiation in the myeloid lineage. Recent evidence has demonstrated that NFAT family members may have roles in regulating AML leukemogenesis and resistance to targeted therapy in myeloid leukaemia. Furthermore, gene expression data from patient samples show that some NFATs are more highly expressed in poorly differentiated AML and after disease relapse, implying that the NFAT family may have roles in specific types of AML. This review outlines the evidence for the role of NFAT in healthy myeloid tissue and explores how NFAT might regulate AML pathogenesis, highlighting the potential to target specific NFAT proteins therapeutically in AML.
引用
收藏
页码:556 / 571
页数:16
相关论文
共 50 条
  • [41] Novel therapies for children with acute myeloid leukaemia
    A S Moore
    P R Kearns
    S Knapper
    A D J Pearson
    C M Zwaan
    [J]. Leukemia, 2013, 27 : 1451 - 1460
  • [42] Independent prognostic variables in acute myeloid leukaemia
    Smith, Matthew L.
    Hills, Robert K.
    Grimwade, David
    [J]. BLOOD REVIEWS, 2011, 25 (01) : 39 - 51
  • [43] Treatment of older patients with acute myeloid leukaemia
    Ferrara, Felicetto
    [J]. LANCET, 2010, 376 (9757) : 1967 - 1968
  • [44] Minimal residual disease in acute myeloid leukaemia
    Yin, JAL
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 119 - 135
  • [45] Preclinical activity of resazurin in acute myeloid leukaemia
    Ha, Trung Quang
    Andresen, Vibeke
    Erikstein, Bjarte Skoe
    Popa, Mihaela
    Gullaksen, Stein-Erik
    Reikvam, Hakon
    Mccormack, Emmet
    Gjertsen, Bjorn Tore
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, : 109 - 119
  • [46] Amplification of mitochondrial DNA in acute myeloid leukaemia
    Boultwood, J
    Fidler, C
    Mills, KI
    Frodsham, PM
    Kusec, R
    Gaiger, A
    Gale, RE
    Linch, DC
    Littlewood, TJ
    Moss, PAH
    Wainscoat, JS
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 426 - 431
  • [47] Relevance of clinical trials in acute myeloid leukaemia
    Tsimberidou, Apostolia M.
    Estey, Elihu
    [J]. HEMATOLOGICAL ONCOLOGY, 2008, 26 (03) : 182 - 183
  • [48] Novel therapies for children with acute myeloid leukaemia
    Moore, A. S.
    Kearns, P. R.
    Knapper, S.
    Pearson, A. D. J.
    Zwaan, C. M.
    [J]. LEUKEMIA, 2013, 27 (07) : 1451 - 1460
  • [49] Immunophenotypic clustering in paediatric acute myeloid leukaemia
    Liu, Hui
    Wu, Kefei
    Hu, Wenting
    Chen, Xiaoxiao
    Tang, Yanjing
    Ma, Yani
    Chen, Changcheng
    Xie, Yangyang
    Yu, Lisha
    Huang, Jun
    Shen, Shuhong
    Wang, Xiang
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (06) : 2275 - 2286
  • [50] Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation
    Zawawi, M. S. F.
    Dharmapatni, A. A. S. S. K.
    Cantley, M. D.
    McHugh, K. P.
    Haynes, D. R.
    Crotti, T. N.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 427 (02) : 404 - 409